Publication | Closed Access
Tricyclic triarylethylene antiestrogens: dibenz[b,f]oxepins, dibenzo[b,f]thiepins, dibenzo[a,e]cyclooctenes, and dibenzo[b,f]thiocins
37
Citations
0
References
1983
Year
Hormonal ContraceptiveGynecologyOrganic ChemistryPharmacotherapyChemistryHeterocycle ChemistryDibenzoxepin Ring SystemBridging Groups OMedicinal ChemistryTricyclic Triarylethylene AntiestrogensHormonal ReceptorAntiestrogenic ActivityEndocrinologyPharmacologyOvarian HormoneEndocrine DisruptorsHeterocyclicNatural SciencesMedicineDerivative (Chemistry)Drug Discovery
The bridging groups O, S, CH2CH2, and SCH2 were used to produce a series of 26 tricyclic triarylethylenes. Their in vitro binding to rat uterine estrogen receptor was measured in a competitive binding assay. Antifertility and uterotrophic tests in rats showed that antiestrogenic activity was present. The most interesting series had a basic side chain, and the most potent compounds were 3-[2-(dimethylamino)ethoxy] -10-ethyl-11-(4-hydroxyphenyl)dibenzo[b,f]thiepin (7b) and 3-[2-(dimethylamino)ethoxy]-11-ethyl-12-(4-hydroxyphenyl)-5,6-dihydrodibenzo[a,e]-cyclooctene (7c), which had good binding (approximately 50% relative to estradiol) and good antiestrogenic activity (ca. one-half of the potency of tamoxifen, III). In this series, the O-bridged compound was the least active, and this is interpreted in terms of the flatness of the dibenzoxepin ring system. Sedative activity was found in some of the compounds.